DiGeorge Syndrome Clinical Presentation

  • Author: Erawati V Bawle, MD, FAAP, FACMG; Chief Editor: Harumi Jyonouchi, MD   more...
 
Updated: May 15, 2012
 

History

The most common reason to suspect chromosome 22q11.2 deletion syndrome is a cardiac anomaly, especially a conotruncal one. Neonatal hypocalcemia should also raise suspicion for this syndrome, especially if the hypocalcemia or heart defect is coupled with cleft palate, which is frequently observed in affected individuals. The characteristic facies of this syndrome are often subtle in infancy and not fully manifested until the child is older; therefore, they are not a common indication for a genetic investigation. The distinctive facial features may even be absent or very subtle in people of African-American or other nonwhite descent. Developmental delay may be mild in infancy or may go unnoticed until the child reaches school age. Additional abnormalities of every organ system have been reported,[10] although, individually, are rare. Details of the common symptoms/anomalies follow.

Cardiac and vascular features

Congenital heart defects are observed in 74-80% of patients. A higher incidence is noted in cases diagnosed during infancy because of the symptomatic nature of the heart lesion. Any conotruncal heart defect can occur. In infancy, tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch are more common; ventricular septal defect (VSD), pulmonary atresia plus VSD, and other conotruncal defects are seen in cases diagnosed after age 2 years. Rare cardiac anomalies include vascular ring anomaly, transposition of great arteries with VSD, coarctation of the aorta,atrial septal defect (ASD), pulmonary stenosis, hypoplastic left heart, and patent ductus arteriosus.

Some patients have vascular anomalies, and those who need pharyngeal surgery should be specifically checked for anomalies of the carotid arteries.

Craniofacial features

Characteristic facies are easier to recognize in white children and consist of a high and broad nasal bridge, long face, narrow palpebral fissures, and micrognathia. Microcephaly and asymmetric crying face may be present. Facial features become more pronounced as the children grow into the second decade.

Hypernasal voice indicates velopharyngeal incompetence (VPI) and is more common than an overt cleft of the secondary palate. VPI may be caused by a submucous cleft palate. An overt cleft palate does improve the chances of an earlier diagnosis.

Poor sucking and nasal regurgitation due to VPI or a submucous cleft palate may be present. The swallowing problem usually resolves by the end of the first year, leaving the child with hypernasal speech as the major remaining manifestation.

Recurrent episodes of otitis media may be observed. Conductive or sensorineural hearing loss (or both) may be present.

Recurrent infections

Recurrent infections secondary to immune deficiency may be observed. The overall incidence of immune dysfunction is 77%.[10]

The characteristic immunodeficiency is a mild-to-moderate defect in T-cell lineage as a consequence of thymic hypoplasia. Naïve T-cell production is usually reduced. Only a small fraction of patients present with marked impairment of T-cell function associated with complete absence of thymus and T cells and severe systemic infections consistent with severe combined immunodeficiency (SCID) phenotype. T-cell functions and numbers that improve with age may be attributed to homeostatic T-cell proliferation secondary to limited T-cell production.

Variable secondary humoral defects, including hypogammaglobulinemia and selective antibody deficiency, may be present.

Impaired T-cell production may predispose patients with 22q11.2 deletion to autoimmune diseases. In a cohort of 195 patients with chromosome 22q11.2 deletion syndrome, various autoimmune diseases, including juvenile rheumatoid arthritis (JRA), idiopathic thrombocytopenic purpura (ITP), and autoimmune hemolytic anemia (AHA), were each more prevalent than in the age-matched general population.[11] No specific pattern of autoimmune diseases appears to be associated with 22q11.2 deletion.

Hypocalcemia

Hypocalcemia due to hypoparathyroidism can cause seizures. The incidence of hypocalcemia varies widely, from 17-60%. This is frequently a self-limiting problem, and approximately 50% of patients are no longer needing calcium supplementation by age 1 year.

Developmental delay/learning difficulties

Developmental delay and learning difficulties are observed in 70-90% of patients. In infancy, developmental milestones are achieved later than expected for age. Delayed language acquisition is often seen in older children.

A frequent pattern of disability is observed,[12] consisting of a low performance intelligence quotient (IQ) compared with verbal IQ, which creates problems with nonverbal learning, abstract reasoning, and math. In school-aged children, full-scale IQ scores can range from average to low average to mild mental retardation. The incidence of mild mental retardation is approximately 30%. Brain anomalies like polymicrogyria and enlarged Sylvian fissures have rarely been noted.

Behavioral abnormalities

Various behavioral abnormalities, including attention deficit disorder, shyness, disinhibition, and autism spectrum disorders, have been reported. The incidence of psychoses such as depression, bipolar disorders, schizophrenia, and anxiety is increased,[13] and some report their prevalence to be about 10%.

In one longitudinal study,[13] 20% of VCFS children in mid adolescence had significant prodromal psychotic symptoms. In their sample, weaker executive functioning and verbal abilities and high levels of odd/eccentric and anxious behaviors in childhood best predicted prodromal psychotic symptoms in adolescence.

Other findings

Kidney and renal pelvis duplications can occur.

Next

Physical

There is considerable variability in individual physical findings and in the organ systems that may be involved.

Patients usually have characteristic facies, which become more pronounced as the child grows into the second decade. These are more commonly and easily recognized in white children. Retrognathia or micrognathia, long face, high and broad nasal bridge, and narrow palpebral fissures are common features, as shown in the image below.

Mother and children with 22q11.2 deletion syndromeMother and children with 22q11.2 deletion syndrome.

Although VPI is more common, a cleft of soft palate or a bifid uvula (associated with a submucous cleft palate) may be present.

Other frequent facial features include small teeth, asymmetric crying face, and down-turned mouth, as shown in the image below.

An African American girl with 22q11.2 deletion synAn African American girl with 22q11.2 deletion syndrome. The same girl in previous image showing an asymmetThe same girl in previous image showing an asymmetric crying face.

Heart murmur and other cardiac findings may be present, depending on the nature of the cardiac lesion.

Long tapering fingers may be present.

Short stature may occur; decrease in the rate of linear growth may suggest rarely seen growth hormone deficiency.

GI anomalies like esophageal atresia and anal atresia or stenosis may be present.

Polydactyly and scoliosis due to vertebral anomalies have been seen in rare cases.

Previous
Next

Causes

Occurrence is sporadic in 85% of cases. Approximately 7% of cases are inherited as dominant, and less than 1% of cases are due to chromosomal rearrangements. The hereditary cases show no predilection in inheritance from the mother or the father. An affected person has a 50% chance of transmitting the condition to his or her child. Wide intrafamily and interfamily variability in clinical manifestations is seen.

Remember that not all patients with DiGeorge syndrome (DGS) have the 22q11.2 microdeletion. Patients with other chromosomal anomalies, such as those with deletion of band 4q, 10p, or 17p; infants of mothers with diabetes; and patients with fetal alcohol syndrome, may show signs of DGS. Chromosome 10p13-p14 deletion is often referred to as DGS2.

Previous
 
 
Contributor Information and Disclosures
Author

Erawati V Bawle, MD, FAAP, FACMG  Retired Professor, Department of Pediatrics, Wayne State University School of Medicine

Erawati V Bawle, MD, FAAP, FACMG is a member of the following medical societies: American College of Medical Genetics and American Society of Human Genetics

Disclosure: Nothing to disclose.

Specialty Editor Board

C Lucy Park  MD, Head, Division of Allergy, Immunology, and Pulmonology, Associate Professor, Department of Pediatrics, University of Illinois at Chicago College of Medicine

C Lucy Park is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Medical Association, Chicago Medical Society, Clinical Immunology Society, and Illinois State Medical Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

John Wilson Georgitis, MD  Consulting Staff, Lafayette Allergy Services

John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society

Disclosure: Nothing to disclose.

David Pallares, MD  Clinical Assistant Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Louisville School of Medicine

David Pallares, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD  Associate Professor, Division of Pulmonary, Allergy/Immunology, and Infectious Diseases, Department of Pediatrics, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Mucosal Immunology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

The author and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Daniel AC Frattarelli, MD, FAAP, to the development and writing of this article.

References
  1. Sedlackova E. [Insufficiency of palatolaryngeal passage as a developmental disorder.]. Cas Lek Cesk. Nov 25 1955;94(47-48):1304-7. [Medline].

  2. Vrticka K. Present-day importance of the velocardiofacial syndrome. To commemorate the late prof. Eva sedlackova, MD, on the 50th anniversary of her original publication. Folia Phoniatr Logop. 2007;50:141-6. [Medline].

  3. Kinouchi A, Mori K, et al. Facial Appearance of Patients with Conotruncal Anomalies. Pediatr Jpn. 1976;17:84-7.

  4. Shprintzen RJ, Goldberg RB, Lewin ML, Sidoti EJ, Berkman MD, Argamaso RV, et al. A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome. Cleft Palate J. Jan 1978;15(1):56-62. [Medline].

  5. de la Chapelle A, Herva R, Koivisto M, Aula P. A deletion in chromosome 22 can cause DiGeorge syndrome. Hum Genet. 1981;57(3):253-6. [Medline].

  6. Emanuel BS. Molecular mechanisms and diagnosis of chromosome 22q11.2 rearrangements. Dev Disabil Res Rev. 2008;14(1):11-8. [Medline].

  7. [Best Evidence] Funato N, Nakamura M, Richardson JA, Srivastava D, Yanagisawa H. Tbx1 regulates oral epithelial adhesion and palatal development. Hum Mol Genet. Mar 8 2012;[Medline].

  8. De Smedt B, Devriendt K, Fryns JP, Vogels A, Gewillig M, Swillen A. Intellectual abilities in a large sample of children with Velo-Cardio-Facial Syndrome: an update. J Intellect Disabil Res. 2007;51:666-70. [Medline].

  9. Shprintzen RJ. Velo-cardio-facial syndrome: 30 years of study. Dev Disabil Res Rev. 2008;14:3-10. [Medline].

  10. McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). Jan 2011;90(1):1-18. [Medline].

  11. Jawad AF, McDonald-Mcginn DM, Zackai E, et al. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr. Nov 2001;139(5):715-23. [Medline].

  12. Furniss F, Biswas AB, Gumber R, Singh N. Cognitive phenotype of velocardiofacial syndrome: a review. Res Dev Disabil. Nov-Dec 2011;32(6):2206-13. [Medline].

  13. Antshel KM, Shprintzen R, Fremont W, Higgins AM, Faraone SV, Kates WR. Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry. Apr 2010;49(4):333-44. [Medline].

  14. [Best Evidence] Bittel DC, Yu S, Newkirk H, Kibiryeva N, Holt A 3rd, Butler MG, et al. Refining the 22q11.2 deletion breakpoints in DiGeorge syndrome by aCGH. Cytogenet Genome Res. 2009;124(2):113-20. [Medline].

  15. Bassett AS, McDonald-McGinn DM, Devriendt K, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr. Aug 2011;159(2):332-9.e1. [Medline]. [Full Text].

  16. Ammann AJ, Wara DW, Cowan MJ, Barrett DJ, Stiehm ER. The DiGeorge syndrome and the fetal alcohol syndrome. Am J Dis Child. Oct 1982;136(10):906-8. [Medline].

  17. Driscoll DA, Budarf ML, Emanuel BS. A genetic etiology for DiGeorge syndrome: consistent deletions and microdeletions of 22q11. Am J Hum Genet. May 1992;50(5):924-33. [Medline].

  18. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug Information Handbook. Cleveland, OH: Lexi-Comp, Inc; 2000-2001.

  19. Goldsobel AB, Haas A, Stiehm ER. Bone marrow transplantation in DiGeorge syndrome. J Pediatr. Jul 1987;111(1):40-4. [Medline].

  20. Greenberg F. DiGeorge syndrome: an historical review of clinical and cytogenetic features. J Med Genet. Oct 1993;30(10):803-6. [Medline].

  21. Hong R. The DiGeorge anomaly. Clin Rev Allergy Imunol. 2001;20(1):43-60.

  22. Hong R. The DiGeorge anomaly (CATCH 22, DiGeorge/velocardiofacial syndrome). Semin Hematol. Oct 1998;35(4):282-90. [Medline].

  23. Keppen LD, Fasules JW, Burks AW, et al. Confirmation of autosomal dominant transmission of the DiGeorge malformation complex. J Pediatr. Sep 1988;113(3):506-8. [Medline].

  24. Kim MS, Basson CT. Wrapping up DiGeorge syndrome in a T-box?. Pediatr Res. Sep 2001;50(3):307-8. [Medline].

  25. Kirkpatrick JA Jr, DiGeorge AM. Congenital absence of the thymus. Am J Roentgenol Radium Ther Nucl Med. May 1968;103(1):32-7. [Medline].

  26. Lammer EJ, Opitz JM. The DiGeorge anomaly as a developmental field defect. Am J Med Genet Suppl. 1986;2:113-27. [Medline].

  27. Markert ML, Boeck A, Hale LP, et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med. Oct 14 1999;341(16):1180-9. [Medline].

  28. McDonald-McGinn DM, Driscoll DA, Emanuel BS, et al. Detection of a 22q11.2 deletion in cardiac patients suggests a risk for velopharyngeal incompetence. Pediatrics. May 1997;99(5):E9. [Medline].

  29. Oskarsdottir S, Persson C, Eriksson BO. Presenting phenotype in 100 children with the 22q11 deletion syndrome. Eur J Pediatr. 2005;164:146-53. [Medline].

  30. Piliero LM, Sanford AN, McDonald-McGinn DM, Zackai EH, Sullivan KE. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood. Feb 1 2004;103(3):1020-5. [Medline].

  31. Robin RH, Shprintzen RJ. Defining The Clinical Spectrum of Deletion 22q11.2. J of Pediatrics. 2005;147:90-6. [Medline].

  32. Schwartz SA. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatr Clin North Am. Dec 2000;47(6):1355-69. [Medline].

  33. Thampakkul S, Ballow M. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Immunol Aller Clin North Am. 2001;21(1):165-84. [Full Text].

  34. Thomas JA, Graham JM Jr. Chromosomes 22q11 deletion syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila). May 1997;36(5):253-66. [Medline].

  35. Towbin JA, Casey B, Belmont J. The molecular basis of vascular disorders. Am J Hum Genet. Mar 1999;64(3):678-84. [Medline].

  36. Wilson DI, Burn J, Scambler P, Goodship J. DiGeorge syndrome: part of CATCH 22. J Med Genet. Oct 1993;30(10):852-6. [Medline].

  37. Wulfsberg EA, Leana-Cox J, Neri G. What's in a name? Chromosome 22q abnormalities and the DiGeorge, velocardiofacial, and conotruncal anomalies face syndromes. Am J Med Genet. Nov 11 1996;65(4):317-9. [Medline].

Previous
Next
 
Mother and children with 22q11.2 deletion syndrome.
An African American girl with 22q11.2 deletion syndrome.
The same girl in previous image showing an asymmetric crying face.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.